Le pancréas est constitué de deux tissus : exocrine et endocrine. Le tissu endocrine est organisé en îlots de Langerhans, comprenant 5 sous-types cellulaires dont les deux principaux (α et β) sécrètent respectivement le glucagon et l’insuline. Le diabète de type 1 est une maladie auto-immune caractérisée par la perte des cellules β et donc une hyperglycémie chronique. Les thérapies actuelles sont efficaces mais contraignantes, amenant une partie de la recherche actuelle à déchiffrer les mécanismes de la genèse des cellules β et/ou de leur régénération pour tenter d’établir des thérapies alternatives. Des études ont permis de caractériser la cascade de facteurs de transcription différentiant les cellules progénitrices pancréatiques durant le développement, dont Neurog3 spécifiant le lignage endocrine et le gène Pax4 favorisant le lignage β. De précédents résultats nous ont amenés à établir l’hypothèse que les cellules canalaires pancréatiques contiendraient une source potentielle de précurseurs, qui par la réexpression de Neurog3 pourraient devenir endocrine, ce que nous avons analysé in vivo après avoir généré les souris transgéniques correspondantes. Nous avons observé un accroissement considérable de la taille des îlots, dû à une augmentation du nombre de chaque sous-type cellulaire endocrine. Nous démontrons que ces cellules endocrines supplémentaires ont bien une origine canalaires, tandis que des études physiologiques indiquent une réponse fonctionnelle de l’insuline suite à une injection de glucose. Finalement, nos analyses apportent également la preuve que le devenir de ces nouvelles cellules endocrines peut être modulé en agissant sur l’activité du gène Pax4. / The pancreas can be divided into two tissue types: exocrine and endocrine. The endocrine tissue is organized into clusters of cells named islets of Langerhans, comprising five cell subtypes of which the two main (α and β) secrete respectively glucagon and insulin. Type 1 diabetes is an auto-immune disease resulting in the loss of pancreatic β-cells and, consequently, in chronic hyperglycemia. Current therapies are efficient but remain highly binding, leading current research to aim at deciphering the β-cell genesis and/or regeneration to potentially establish new therapies. Many studies characterized the specific cascade of transcription factors differentiating pancreatic progenitor cells during development, including Neurog3 specifying the endocrine lineage and Pax4 favoring the β-cell lineage. Previous results obtained in the lab led us to establish the hypothesis that pancreatic ducts may contain a potential source of progenitor cells, which could become endocrine cells through re-expression of Neurog3. Thus, we investigated the consequences of the ectopic misexpression of Neurog3 in pancreatic duct cells in vivo. Using this strategy, we observed a dramatic increase in islet size, due to an augmentation in all endocrine cells types. Lineage tracing allowed us to demonstrate that the new endocrine cells have a ductal origin, while physiological studies displayed functional insulin response upon a glucose bolus. Finally, our analyses also demonstrated that the fate of these newly generated endocrine cells could be modulated by acting on the Pax4 gene.

<p>Understanding signalling pathways that control pancreatic endocrine tumour (PET) development and proliferation may reveal novel targets for therapeutic intervention. The pathogenesis for sporadic and hereditary PETs, apart from mutations of the <i>MEN1</i> and <i>VHL</i> tumour suppressor genes, is still elusive. The protein product of the <i>MEN1</i> gene, menin, regulates many genes. The aim of this thesis was to identify genes involved in pancreatic endocrine tumourigenesis, with special reference to Notch signalling.</p><p>Messenger RNA and protein expression of NOTCH1, HES1, HEY1, ASCL1, NEUROG3, NEUROD1, DLK1, POU3F4, PDX1, RPL10, DKK1 and TPH1 were studied in human PETs, sporadic and MEN 1, as well as in tumours from heterozygous <i>Men1</i> mice. For comparison, normal and <i>MEN1</i> non-tumourous human and mouse pancreatic specimens were used. Nuclear expression of HES1 was consistently absent in PETs. In mouse tumours this coincided with loss of menin expression, and there was a correlation between <i>Men1</i> expression and several Notch signalling factors. A new phenotype consisting of numerous menin-expressing endocrine cell clusters, smaller than islets, was found in <i>Men1</i> mice. Expression of NEUROG3 and NEUROD1 was predominantly localised to the cytoplasm in PETs and islets from MEN 1 patients and <i>Men1</i> mice, whereas expression was solely nuclear in wt mice. Differences in expression levels of Pou3f4, Rpl10 and Dlk1 between islets of <i>Men1</i> and wt mice were observed.</p><p>In addition, combined RNA interference and microarray expression analysis in the pancreatic endocrine cell line BON1 identified 158 target genes of ASCL1. For two of these, DKK1 (a negative regulator of the WNT/β-catenin signalling pathway) and TPH1, immunohistochemistry was performed on PETs. In concordance with the microarray finding, DKK1 expression showed an inverse relation to ASCL1 expression.</p><p>Altered subcellular localisation of HES1, NEUROD1 and NEUROG3 and down-regulation of DKK1 may contribute to tumourigenesis.</p>

Understanding signalling pathways that control pancreatic endocrine tumour (PET) development and proliferation may reveal novel targets for therapeutic intervention. The pathogenesis for sporadic and hereditary PETs, apart from mutations of the MEN1 and VHL tumour suppressor genes, is still elusive. The protein product of the MEN1 gene, menin, regulates many genes. The aim of this thesis was to identify genes involved in pancreatic endocrine tumourigenesis, with special reference to Notch signalling. Messenger RNA and protein expression of NOTCH1, HES1, HEY1, ASCL1, NEUROG3, NEUROD1, DLK1, POU3F4, PDX1, RPL10, DKK1 and TPH1 were studied in human PETs, sporadic and MEN 1, as well as in tumours from heterozygous Men1 mice. For comparison, normal and MEN1 non-tumourous human and mouse pancreatic specimens were used. Nuclear expression of HES1 was consistently absent in PETs. In mouse tumours this coincided with loss of menin expression, and there was a correlation between Men1 expression and several Notch signalling factors. A new phenotype consisting of numerous menin-expressing endocrine cell clusters, smaller than islets, was found in Men1 mice. Expression of NEUROG3 and NEUROD1 was predominantly localised to the cytoplasm in PETs and islets from MEN 1 patients and Men1 mice, whereas expression was solely nuclear in wt mice. Differences in expression levels of Pou3f4, Rpl10 and Dlk1 between islets of Men1 and wt mice were observed. In addition, combined RNA interference and microarray expression analysis in the pancreatic endocrine cell line BON1 identified 158 target genes of ASCL1. For two of these, DKK1 (a negative regulator of the WNT/β-catenin signalling pathway) and TPH1, immunohistochemistry was performed on PETs. In concordance with the microarray finding, DKK1 expression showed an inverse relation to ASCL1 expression. Altered subcellular localisation of HES1, NEUROD1 and NEUROG3 and down-regulation of DKK1 may contribute to tumourigenesis.